MX2020003125A - Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. - Google Patents
Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.Info
- Publication number
- MX2020003125A MX2020003125A MX2020003125A MX2020003125A MX2020003125A MX 2020003125 A MX2020003125 A MX 2020003125A MX 2020003125 A MX2020003125 A MX 2020003125A MX 2020003125 A MX2020003125 A MX 2020003125A MX 2020003125 A MX2020003125 A MX 2020003125A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- derivative conjugate
- pyrrolobenzodiazepine derivative
- novel
- pyrrolobenzodiazepine
- Prior art date
Links
- 102100038449 Claudin-6 Human genes 0.000 abstract 1
- 102100026097 Claudin-9 Human genes 0.000 abstract 1
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 abstract 1
- 101000912661 Homo sapiens Claudin-9 Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención proporciona un derivado de anticuerpo-pirrolodiazepina novedoso y un conjugado de anticuerpo-derivado de pirrolodiazepina novedoso que utiliza el mismo y un anticuerpo CLDN6 y/o CLDN9 novedoso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017190713 | 2017-09-29 | ||
PCT/JP2018/036252 WO2019065964A1 (ja) | 2017-09-29 | 2018-09-28 | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003125A true MX2020003125A (es) | 2020-10-01 |
Family
ID=65902559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003125A MX2020003125A (es) | 2017-09-29 | 2018-09-28 | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. |
Country Status (16)
Country | Link |
---|---|
US (4) | US11628223B2 (es) |
EP (1) | EP3690038A4 (es) |
JP (4) | JP7273716B2 (es) |
KR (1) | KR20200061376A (es) |
CN (4) | CN116999573A (es) |
AU (1) | AU2018342527A1 (es) |
BR (1) | BR112020004126A2 (es) |
CA (4) | CA3125713A1 (es) |
CO (1) | CO2020004921A2 (es) |
IL (4) | IL301637A (es) |
MX (1) | MX2020003125A (es) |
PH (1) | PH12020500398A1 (es) |
RU (1) | RU2020109412A (es) |
SG (1) | SG11202001430SA (es) |
TW (4) | TW202404649A (es) |
WO (1) | WO2019065964A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116999573A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体-药物偶联物及其制造方法、药物组合物及其在制备治疗肿瘤的药物中的应用 |
GB201803342D0 (en) * | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP3876998A1 (en) * | 2018-11-05 | 2021-09-15 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
AU2019379418A1 (en) * | 2018-11-14 | 2021-06-03 | Daiichi Sankyo Company, Limited | Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate |
KR20210143237A (ko) * | 2019-03-25 | 2021-11-26 | 다이이찌 산쿄 가부시키가이샤 | 항체-피롤로벤조디아제핀 유도체 컨쥬게이트 |
US20220177601A1 (en) * | 2019-03-25 | 2022-06-09 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate |
CA3139180A1 (en) * | 2019-03-27 | 2020-10-01 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
WO2021151119A1 (en) * | 2020-01-23 | 2021-07-29 | Exuma Biotech Corp. | Chimeric antigen receptors to her2 and methods of use thereof |
JPWO2022050300A1 (es) | 2020-09-02 | 2022-03-10 | ||
WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
CA3212665A1 (en) * | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
WO2022191313A1 (ja) | 2021-03-12 | 2022-09-15 | 第一三共株式会社 | 糖鎖及び糖鎖を含む医薬品の製造方法 |
WO2023051814A1 (zh) | 2021-09-30 | 2023-04-06 | 江苏恒瑞医药股份有限公司 | 吡咯并苯并二氮杂卓类衍生物及其偶联物、其制备方法及其应用 |
TW202333798A (zh) * | 2021-12-17 | 2023-09-01 | 大陸商信達生物製藥(蘇州)有限公司 | 靶向claudin 18.2的抗體-藥物偶聯物 |
WO2023141855A1 (en) * | 2022-01-27 | 2023-08-03 | Glyco-Therapy Biotechnology Co., Ltd. | Protein conjugates with multiple payloads and methods for making the same |
WO2024043341A1 (ja) * | 2022-08-26 | 2024-02-29 | ペプチドリーム株式会社 | シクロアルキン誘導体 |
CN117257977A (zh) * | 2023-11-07 | 2023-12-22 | 正大天晴药业集团南京顺欣制药有限公司 | 用于制备抗体药物偶联物的方法 |
Family Cites Families (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57131791A (en) | 1980-12-31 | 1982-08-14 | Fujisawa Pharmaceut Co Ltd | Benzodiazepine derivative and its preparation |
JPS5841884A (ja) | 1981-09-07 | 1983-03-11 | Fujisawa Pharmaceut Co Ltd | ベンゾジアゼピン誘導体の製造法 |
US4427588A (en) | 1982-11-08 | 1984-01-24 | Bristol-Myers Company | Process for conversion of oxotomaymycin to tomaymycin |
JPS63107992A (ja) | 1986-10-24 | 1988-05-12 | Meiji Seika Kaisha Ltd | 新規抗腫瘍性抗生物質sf2364物質及びその製造法 |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
JPH01121296A (ja) | 1987-11-02 | 1989-05-12 | Kyowa Hakko Kogyo Co Ltd | 新規物質dc−105およびその製造法 |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
JP3507073B2 (ja) | 1992-03-24 | 2004-03-15 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的結合対の成員の製造方法 |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
EP1193270B1 (en) | 1998-08-27 | 2003-05-14 | Spirogen Limited | Pyrrolobenzodiazepines |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
BRPI0213846B8 (pt) | 2001-11-01 | 2021-05-25 | Uab Research Foundation | composição que compreende um anticorpo que liga especificamente uma dr5 do receptor de trail e um ou mais agentes terapêuticos |
CN100360567C (zh) | 2002-03-01 | 2008-01-09 | 免疫医疗公司 | Rs7抗体 |
GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
DE60326060D1 (de) | 2003-03-31 | 2009-03-19 | Council Scient Ind Res | Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung |
AU2003223107A1 (en) | 2003-03-31 | 2004-10-25 | Council Of Scentific And Industrial Research | Pyrene-linked pyrrolo (2,1-c) (1,4) benzodiazepine derivatives useful as anticancer agents |
RU2314309C2 (ru) | 2003-03-31 | 2008-01-10 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе |
GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
AU2004284075A1 (en) * | 2003-10-22 | 2005-05-06 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
JP4833663B2 (ja) | 2003-12-31 | 2011-12-07 | カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ | C2−フルオロピロロ[2,1−c][1,4]ベンゾジアゼピン二量体 |
GB2424884B (en) | 2003-12-31 | 2008-06-11 | Council Scient Ind Res | C-8 linked pyrrolo[2,1-c][1,4]benzodiazepine-acridone/acridine hybrids |
GB0404574D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Amino acids |
GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
AU2005219626B2 (en) | 2004-03-01 | 2010-11-18 | Medimmune Limited | 11-hydroxy-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of C2 substituted pyrrolobenzodiazepines |
WO2005085260A1 (en) | 2004-03-09 | 2005-09-15 | Spirogen Limited | Pyrrolobenzodiazepines |
GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
AU2006238686B2 (en) | 2005-04-21 | 2011-10-06 | Medimmune Limited | Pyrrolobenzodiazepines |
PT1813614E (pt) | 2006-01-25 | 2012-01-09 | Sanofi Sa | Agentes citotóxicos compreendendo novos derivados de tomaimicina |
WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
KR101528939B1 (ko) | 2006-07-18 | 2015-06-15 | 사노피 | 암 치료를 위한 epha2에 대한 길항제 항체 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
CN101918450A (zh) | 2008-01-11 | 2010-12-15 | 国立大学法人东京大学 | 抗cldn6抗体 |
GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819097D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
WO2010065159A1 (en) | 2008-12-02 | 2010-06-10 | Oregon Health & Science University | Inhibition of dna polymerases to augment chemotherapeutic and antimicrobial agents |
IL271761B (en) | 2009-02-05 | 2022-09-01 | Immunogen Inc | (12as)-8-methoxy-9-benzyloxy-11,12,12a,13-tetrahydro-6h-indolo[2,1-c][1,4]benzodiazepine-6-one, 4-benzyloxy-5-methoxy -2-nitrobenzoic acid and a process for their preparation |
LT2398902T (lt) | 2009-02-20 | 2023-12-27 | Astellas Pharma Inc. | Vėžio diagnostikos ir gydymo būdai bei kompozicijos |
EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
LT2499161T (lt) | 2009-11-11 | 2017-11-27 | Ganymed Pharmaceuticals Gmbh | Specifiniai antikūnai, skirti klaudinui 6 (cldn6) |
GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
US9242013B2 (en) | 2010-04-15 | 2016-01-26 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
PE20130342A1 (es) | 2010-04-15 | 2013-04-20 | Spirogen Sarl | Pirrolobenzodiacepinas y conjugados de las mismas |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
CA2822037A1 (en) | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Methods for treating hcv |
RU2748733C2 (ru) | 2011-02-15 | 2021-05-31 | Иммуноджен, Инк. | Цитотоксические производные бензодиазепина |
US10851174B2 (en) | 2011-03-03 | 2020-12-01 | University Of Maryland, Baltimore | Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof |
US9175326B2 (en) | 2011-03-03 | 2015-11-03 | University Of Maryland, Baltimore | Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae |
LT3026064T (lt) | 2011-05-13 | 2019-01-25 | Ganymed Pharmaceuticals Gmbh | Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6 |
JP2014200118A (ja) | 2011-07-28 | 2014-10-23 | 三洋電機株式会社 | 電池駆動機器及び電池パック |
KR101860174B1 (ko) | 2011-09-20 | 2018-05-21 | 메디뮨 리미티드 | 표적 접합체 내의 내포를 위한 비대칭 이량체 pbd 화합물로서 피롤로벤조디아제핀 |
JP6393617B2 (ja) | 2011-10-14 | 2018-09-19 | シアトル ジェネティクス,インコーポレーテッド | ピロロベンゾジアゼピンおよび標的コンジュゲート |
EP2753178B1 (en) | 2011-10-14 | 2017-12-06 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
AU2012322932B2 (en) | 2011-10-14 | 2016-11-10 | Medimmune Limited | Pyrrolobenzodiazepines |
EA029046B1 (ru) | 2011-10-14 | 2018-02-28 | Медимьюн Лимитед | Пирролобензодиазепины и промежуточные соединения для их получения, способы их синтеза |
PT2750713E (pt) | 2011-10-14 | 2016-01-20 | Genentech Inc | Pirrolobenzodiazepinas e conjugados das mesmas |
MX341523B (es) | 2011-10-14 | 2016-08-24 | Medimmune Ltd | Pirrolobenzodiazepinas. |
EP2812442B9 (en) | 2012-02-10 | 2023-02-15 | University of Maryland, Baltimore | Chemoenzymatic glycoengineering of antibodies and fc fragments thereof |
US9714298B2 (en) | 2012-04-09 | 2017-07-25 | Daiichi Sankyo Company, Limited | Anti-FGFR2 antibodies and methods of use thereof for treating cancer |
CN104540827B (zh) | 2012-04-30 | 2018-03-23 | Ucl商业有限公司 | 吡咯并苯并二氮杂卓 |
MX369715B (es) | 2012-04-30 | 2019-11-20 | Ucl Business Plc | Pirrolobenzodiacepinas. |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
BR112015000441A2 (pt) | 2012-07-09 | 2017-12-19 | Genentech Inc | imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22 |
IN2014DN10652A (es) | 2012-07-09 | 2015-09-11 | Genentech Inc | |
EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
EP3632471A1 (en) | 2012-10-11 | 2020-04-08 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
KR101995621B1 (ko) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항-cd22 항체 컨주게이트 |
ES2640449T3 (es) | 2012-10-12 | 2017-11-03 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-her2-Pirrolobenzodiazepinas |
JP6367204B2 (ja) | 2012-10-12 | 2018-08-01 | メドイミューン・リミテッドMedImmune Limited | 結合用のピロロベンゾジアゼピン誘導体の合成および中間体 |
CA2885315C (en) | 2012-10-12 | 2020-06-23 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
CA2887895C (en) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd19 antibody conjugates |
ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
WO2014057118A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
JP6270859B2 (ja) | 2012-10-12 | 2018-01-31 | エイディーシー・セラピューティクス・エス・アー・エール・エルAdc Therapeutics Sarl | ピロロベンゾジアゼピン−抗体結合体 |
RS53818B1 (en) | 2012-10-12 | 2015-06-30 | Spirogen Sàrl | PIROLOBENZODIAZEPINI I NJIHOVI conjugated |
WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
CN110201186A (zh) | 2012-10-23 | 2019-09-06 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
WO2014075697A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
MX369276B (es) | 2012-11-13 | 2019-11-04 | Biontech Ag | Agentes para tratamiento de enfermedades cancerosas que expresan claudina. |
CN110452242A (zh) | 2012-12-21 | 2019-11-15 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
SI2958944T1 (sl) | 2013-02-22 | 2019-08-30 | Abb Vie Stemcentrx Llc | Konjugati protiDLL3-protitelo-PBD in njihove uporabe |
JP6340019B2 (ja) * | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
ES2843786T3 (es) | 2013-03-13 | 2021-07-20 | Seagen Inc | Filtración con carbono activado para la purificación de ADC de benzodiazepina |
KR102057755B1 (ko) | 2013-03-13 | 2019-12-19 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
MX2015011367A (es) | 2013-03-13 | 2015-12-16 | Seattle Genetics Inc | Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco. |
WO2014174111A1 (en) | 2013-04-26 | 2014-10-30 | Pierre Fabre Medicament | Axl antibody-drug conjugate and its use for the treatment of cancer |
WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
SG11201601375VA (en) | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Engineered anti-dll3 conjugates and methods of use |
CN115124573A (zh) | 2013-09-02 | 2022-09-30 | 杭州多禧生物科技有限公司 | 应用于细胞结合分子-药物共轭体的新型细胞毒性分子 |
KR102272792B1 (ko) | 2013-09-30 | 2021-07-05 | 광저우 이노케어 파마 테크 씨오., 엘티디. | Btk의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도 |
JP6494519B6 (ja) | 2013-09-30 | 2019-07-31 | 第一三共株式会社 | 抗lps o11抗体 |
WO2015052533A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
EP2935608A1 (en) | 2013-10-14 | 2015-10-28 | SynAffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
EP3057618B1 (en) | 2013-10-14 | 2022-12-14 | SynAffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
CN105829543B (zh) | 2013-10-14 | 2021-06-01 | 西纳福克斯股份有限公司 | 糖基改造的抗体、抗体-缀合物及其制备方法 |
US9987373B2 (en) | 2013-10-14 | 2018-06-05 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
HUE051389T2 (hu) | 2013-10-15 | 2021-03-01 | Seagen Inc | Pegilezett gyógyszer-linkerek ligandum-gyógyszer konjugátum javított farmakokinetikájához |
CN105813650A (zh) * | 2013-11-06 | 2016-07-27 | 施特姆森特克斯股份有限公司 | 新型抗-密蛋白抗体和使用方法 |
BR112016014126B1 (pt) | 2013-12-16 | 2023-02-14 | Medimmune Limited | Composto não-peptídico, conjugados de anticorpo-fármaco do mesmo, uso dos ditos conjugados para o tratamento de câncer e composição farmacêutica que compreende os mesmos |
AU2014369019B2 (en) | 2013-12-19 | 2020-09-17 | Seagen Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
KR102535900B1 (ko) | 2013-12-25 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | 항 trop2 항체-약물 컨쥬게이트 |
JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
AU2015239683B2 (en) | 2014-04-01 | 2019-08-22 | Astellas Pharma Inc. | Claudin-6-Specific immunoreceptors and T cell epitopes |
WO2015157125A1 (en) * | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity |
JP6592008B2 (ja) * | 2014-04-23 | 2019-10-16 | エックス−アールエックス, インコーポレイテッド | オートタキシンの置換n−(2−アミノ)−2−オキソエチルベンズアミド阻害剤およびそれらの調製、ならびにlpa依存性またはlpa媒介性疾患の処置における使用 |
WO2016024195A1 (en) | 2014-08-12 | 2016-02-18 | Novartis Ag | Anti-cdh6 antibody drug conjugates |
WO2016036804A1 (en) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
TW201609152A (zh) | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
MA40921A (fr) | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
US11559581B2 (en) | 2015-01-09 | 2023-01-24 | Oxford University Innovation Limited | Antibody conjugates and methods of making the antibody conjugates |
WO2016115191A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
CN106146666B (zh) | 2015-03-26 | 2019-09-06 | 科济生物医药(上海)有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
WO2016180467A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
MD3313845T2 (ro) | 2015-06-29 | 2021-02-28 | Immunogen Inc | Conjugați cu anticorpi având cisteină modificată prin inginerie genetică |
HUE053619T2 (hu) | 2015-06-29 | 2021-07-28 | Immunogen Inc | Anti-CD123 antitestek és konjugátumok és ezek származékai |
EA201890158A1 (ru) | 2015-06-30 | 2018-06-29 | Сиэтл Дженетикс, Инк. | Антитела против ntb-a и связанные композиции и способы |
JP6752203B2 (ja) | 2015-07-16 | 2020-09-09 | 第一三共株式会社 | 新規EndoS変異酵素 |
GB201513607D0 (en) | 2015-07-31 | 2015-09-16 | Feingold Jay M | Pyrrolobenzodiazepine-antibody conjugates |
WO2015155753A2 (en) | 2015-08-10 | 2015-10-15 | Suzhou M-Conj Biotech Co., Ltd | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
SG11201804673WA (en) | 2015-12-04 | 2018-06-28 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
GB201602363D0 (en) * | 2016-02-10 | 2016-03-23 | Adc Therapeutics Sa And Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
TW201808936A (zh) | 2016-05-18 | 2018-03-16 | 美商梅爾莎納醫療公司 | 吡咯并苯并二氮呯類及其共軛物 |
EP4159749A3 (en) | 2016-07-01 | 2023-06-14 | Daiichi Sankyo Company, Limited | A method for producing fc-containing molecule with remodeled sugar chain |
WO2018054484A1 (en) | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
WO2018107116A1 (en) | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
WO2019048040A1 (en) | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
CN111565744A (zh) | 2017-09-18 | 2020-08-21 | 加利福尼亚大学董事会 | 紧密连接蛋白6抗体和治疗癌症的方法 |
CN116999573A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体-药物偶联物及其制造方法、药物组合物及其在制备治疗肿瘤的药物中的应用 |
US20220177601A1 (en) | 2019-03-25 | 2022-06-09 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate |
KR20210143237A (ko) | 2019-03-25 | 2021-11-26 | 다이이찌 산쿄 가부시키가이샤 | 항체-피롤로벤조디아제핀 유도체 컨쥬게이트 |
CA3139180A1 (en) | 2019-03-27 | 2020-10-01 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
-
2018
- 2018-09-28 CN CN202311002068.9A patent/CN116999573A/zh active Pending
- 2018-09-28 CA CA3125713A patent/CA3125713A1/en active Pending
- 2018-09-28 MX MX2020003125A patent/MX2020003125A/es unknown
- 2018-09-28 IL IL301637A patent/IL301637A/en unknown
- 2018-09-28 CN CN201880063626.3A patent/CN111164208B/zh active Active
- 2018-09-28 CN CN202311002058.5A patent/CN116999572A/zh active Pending
- 2018-09-28 IL IL273471A patent/IL273471B2/en unknown
- 2018-09-28 US US16/651,501 patent/US11628223B2/en active Active
- 2018-09-28 JP JP2019545680A patent/JP7273716B2/ja active Active
- 2018-09-28 SG SG11202001430SA patent/SG11202001430SA/en unknown
- 2018-09-28 CA CA3126646A patent/CA3126646A1/en active Pending
- 2018-09-28 IL IL301638A patent/IL301638A/en unknown
- 2018-09-28 TW TW112140160A patent/TW202404649A/zh unknown
- 2018-09-28 KR KR1020207011831A patent/KR20200061376A/ko not_active Application Discontinuation
- 2018-09-28 CA CA3078218A patent/CA3078218C/en active Active
- 2018-09-28 CN CN202311002067.4A patent/CN117003875A/zh active Pending
- 2018-09-28 BR BR112020004126-2A patent/BR112020004126A2/pt unknown
- 2018-09-28 EP EP18862011.6A patent/EP3690038A4/en active Pending
- 2018-09-28 CA CA3177158A patent/CA3177158A1/en active Pending
- 2018-09-28 WO PCT/JP2018/036252 patent/WO2019065964A1/ja active Application Filing
- 2018-09-28 RU RU2020109412A patent/RU2020109412A/ru unknown
- 2018-09-28 AU AU2018342527A patent/AU2018342527A1/en active Pending
- 2018-09-28 TW TW112140159A patent/TW202404648A/zh unknown
- 2018-09-28 TW TW107134301A patent/TWI820044B/zh active
- 2018-09-28 TW TW112140158A patent/TW202405006A/zh unknown
- 2018-09-28 IL IL301636A patent/IL301636A/en unknown
-
2020
- 2020-02-27 PH PH12020500398A patent/PH12020500398A1/en unknown
- 2020-04-21 CO CONC2020/0004921A patent/CO2020004921A2/es unknown
-
2021
- 2021-11-05 JP JP2021180848A patent/JP7133079B2/ja active Active
- 2021-12-06 US US17/543,697 patent/US11583590B2/en active Active
-
2022
- 2022-04-05 US US17/714,032 patent/US20230084707A1/en active Pending
- 2022-06-26 US US17/849,688 patent/US20220395579A1/en active Pending
-
2023
- 2023-02-17 JP JP2023023178A patent/JP2023062094A/ja active Pending
- 2023-02-17 JP JP2023023179A patent/JP2023062095A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500398A1 (en) | Antibody-pyrrolobenzodiazepine derivative conjugate | |
MX2021006235A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
MX2019007021A (es) | Anticuerpos il-11ra. | |
AU2018258581A8 (en) | RAF-degrading conjugate compounds | |
EP3626825A4 (en) | ANTI-CDH6 ANTIBODY AND ANTI-CDH6 ANTIBODY CONJUGATE-DRUG | |
IL277072A (en) | Anti-claudin antibodies 18.2 | |
WO2018109174A3 (en) | Il-11 antibodies | |
SG10201803042PA (en) | Anti-tim-3 antibodies | |
EP3572428A4 (en) | ANTI-GPR20 ANTIBODY AND ANTI-GPR20 ANTIBODY MEDICINAL CONJUGATE | |
PH12016502142A1 (en) | Anti-ptk7 antibody-drug conjugates | |
EP3801634A4 (en) | TUMOR MICROENVIRONMENT ACTIVATED DRUG-BINDER CONJUGATE AND USES THEREOF | |
MX2017002333A (es) | Conjugados novedosos de glicano y uso de los mismos. | |
IL278877B1 (en) | Amino-pyrazinecarboxamide compounds, conjugates and their uses | |
WO2018071910A3 (en) | Anti-il1-rap antibodies | |
EP3692072A4 (en) | ANTI-HLA-DQ2.5 ANTIBODIES | |
EP3694544A4 (en) | MODULATION OF IMMUNE REACTION USING ANTIBODY-ACTIVE CONJUGATES | |
EP3843736A4 (en) | ISOQUINOLINE STEROID CONJUGATES AND USES THEREOF | |
EP3735987A4 (en) | AMBANITIN ANTIBODY CONJUGATE | |
NZ742805A (en) | Anti-cd22 antibody-maytansine conjugates and methods of use thereof | |
GB201614162D0 (en) | Antibodies, uses thereof and conjugates thereof | |
MX2023006458A (es) | Oligosacaridos inmunomoduladores. | |
EP3620471A4 (en) | ANTIBODY-ANTI-FIBRIN DRUG CONJUGATE INSOLUBLE, POSSIBLE TO BE CLIVID BY PLASMINE | |
EP3441088A4 (en) | ANTIBODY-ACTIVE SUBSTANCE CONJUGATE WITH MODIFIED ANTIBODY | |
SG11202011232VA (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
EP3885362A4 (en) | ANTIBODY CONJUGATE |